ArticleMolecular and clinical oncology2017

Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma.

Nobuki Furubayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.